Feb 01st 2013 - Edison Investment Research today published a report on Proteome Sciences (PRM.L, LSE:PRM, LON:PRM) entitled "Major Deal Soon, Albeit A Bit Delayed". In summary, the report says:
Proteome Sciences expects to sign a major PS Biomarker Service contract during Q113. It had hoped to have concluded the deal in Q412, thus we have reduced our estimates in FY12. However, we still forecast that Proteome Sciences will be profitable in FY13 as the company has a strong order book and expects to sign more stroke biomarker licensing agreements this year. Proteome Sciences is also in discussion with prospective partners for its CK1δ inhibitors for Alzheimer’s disease (AD), having reported that these compounds have shown significant activity in in vivo models. Our valuation is reduced by £4m to £126m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »